J 2009

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

SALAJ, Peter, Petr BRABEC, Miroslav PENKA, V. POHLREICHOVÁ, Petr SMEJKAL et. al.

Basic information

Original name

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.

Authors

SALAJ, Peter (203 Czech Republic, guarantor), Petr BRABEC (203 Czech Republic), Miroslav PENKA (203 Czech Republic), V. POHLREICHOVÁ (203 Czech Republic), Petr SMEJKAL (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic) and U. HEDNER (203 Czech Republic)

Edition

Haemophilia, 2009, 1351-8216

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.505

RIV identification code

RIV/00216224:14110/09:00039183

Organization unit

Faculty of Medicine

UT WoS

000265409600014

Keywords in English

bleeding; dose; haemophilia; inhibitors; registry; rFVIIa
Změněno: 4/3/2010 15:31, Ing. Petr Brabec, Ph.D.

Abstract

V originále

Identifying haemophilia patients with inhibitors for clinical trials is difficult due to the limited number of patients available. Registries are therefore being established as an additional means of data collection. The aim of this study was to investigate the effect of different recombinant activated factor VII (rFVIIa; NovoSeven((R))) dose ranges and dosing schedules on the incidence of re-bleeding in haemophilia patients with inhibitors. In this retrospective, uncontrolled study, data on the bleeding patterns of adult haemophilia patients with high responding inhibitors were analysed.